Vaccines

Canadians want COVID-19 vaccine, progress slow

Thursday, July 2, 2020 - 9:45am

According to Meladul Haq Ahmadzai, CEO of Taleam Systems and a Global Health researcher explains that everyone wants a vaccine cure in Canada, but the progress is slow.

Key Points: 
  • According to Meladul Haq Ahmadzai, CEO of Taleam Systems and a Global Health researcher explains that everyone wants a vaccine cure in Canada, but the progress is slow.
  • Ahmadzai says, Some scientists have said that a vaccine would be available at the end of the year, but others predict a vaccine would be created much faster.
  • During COVID-19 pandemic, health institutions in Canada werent prepared to respond to the Coronavirus due to limited health stock quantity.
  • Canada lost 2 million jobs in April 2020 , were mostly or all eliminated because of the effects of the virus.

Bavarian Nordic Announces European Marketing Authorization for Ebola Vaccine

Wednesday, July 1, 2020 - 2:23pm

COPENHAGEN, Denmark, July 1, 2020 Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced todaythat the European Commission has granted marketing authorization for MVABEA (MVA-BN Filo) together with ZABDENO (Ad26.ZEBOV), which collectively constitute Janssens Ebola vaccine regimen.

Key Points: 
  • COPENHAGEN, Denmark, July 1, 2020 Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced todaythat the European Commission has granted marketing authorization for MVABEA (MVA-BN Filo) together with ZABDENO (Ad26.ZEBOV), which collectively constitute Janssens Ebola vaccine regimen.
  • The marketing authorization has been granted to Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson who obtained a worldwide license to develop, manufacture and commercialize MVA-BN Filo from Bavarian Nordic in 2014.
  • The Ebola vaccine regimen is specifically designed to induce long-term immunity against the Ebola virus, in adults and children aged one year and above.
  • We are proud to have supported the development of a new Ebola vaccine, which represents the second European approval of a product based on our MVA-BN platform technology, said Paul Chaplin, President & CEO of Bavarian Nordic.

Analysis of the Emerging Disease Landscape: Novel Coronavirus (COVID-19) - May 2020 - ResearchAndMarkets.com

Wednesday, July 1, 2020 - 1:20pm

The "Analysis of the Emerging Disease Landscape - COVID-19 - May 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Analysis of the Emerging Disease Landscape - COVID-19 - May 2020" report has been added to ResearchAndMarkets.com's offering.
  • The epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space.
  • The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions.
  • A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring.

Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

Wednesday, July 1, 2020 - 11:00am

In addition, pandemic influenza, such as the H1N1 Swine Flu pandemic of 2009, is a constant global threat.

Key Points: 
  • In addition, pandemic influenza, such as the H1N1 Swine Flu pandemic of 2009, is a constant global threat.
  • BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine.
  • In a total of seven completed Phase 1/2 and Phase 2 clinical trials enrolling 818 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic.
  • The ongoing pivotal Phase 3 clinical trial aims to assess safety and effectiveness of M-001 in reducing flu illness and severity.

Intravacc to In-license CimCure's iBoost Technology, Expanding its Vaccine Platform Portfolio

Wednesday, July 1, 2020 - 8:00am

This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.

Key Points: 
  • This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.
  • iBoost is currently applied to elicit antibody responses against the tumor vasculature, a strategy that conquers the problem of drug resistance.
  • By using the patented iBoost technology, Intravacc and CimCure are also involved in the joint development of a COVID-19 vaccine.
  • Intravacc also has its own proprietary vaccine platform, and established state-of-the-art research and (GMP) production facilities.

Intravacc to In-license CimCure's iBoost Technology, Expanding its Vaccine Platform Portfolio

Wednesday, July 1, 2020 - 8:01am

This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.

Key Points: 
  • This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.
  • iBoost is currently applied to elicit antibody responses against the tumor vasculature, a strategy that conquers the problem of drug resistance.
  • By using the patented iBoost technology, Intravacc and CimCure are also involved in the joint development of a COVID-19 vaccine.
  • Intravacc also has its own proprietary vaccine platform, and established state-of-the-art research and (GMP) production facilities.

COVID-19 Rapid Summary: Immune response and vaccine development

Wednesday, July 1, 2020 - 12:05am

The House of Lords Science and Technology Committee is producing rapid summaries of oral evidence sessions, aimed at providing the public with the latest information on the Science of COVID-19.

Key Points: 
  • The House of Lords Science and Technology Committee is producing rapid summaries of oral evidence sessions, aimed at providing the public with the latest information on the Science of COVID-19.
  • This summary covers two evidence panels on Tuesday 23 June, where we heard from experts including those leading key vaccine development projects in the UK, about the immune response to the virus and the development of vaccines.

COVID-19 Rapid Summary: Immune response and vaccine development

Wednesday, July 1, 2020 - 12:05am

The House of Lords Science and Technology Committee is producing rapid summaries of oral evidence sessions, aimed at providing the public with the latest information on the Science of COVID-19.

Key Points: 
  • The House of Lords Science and Technology Committee is producing rapid summaries of oral evidence sessions, aimed at providing the public with the latest information on the Science of COVID-19.
  • This summary covers two evidence panels on Tuesday 23 June, where we heard from experts including those leading key vaccine development projects in the UK, about the immune response to the virus and the development of vaccines.

New Strategy Emerges for Vaccine Against Methicillin-Resistant Staphylococcal aureus

Tuesday, June 30, 2020 - 3:00pm

The new vaccination strategy, developed by researchers at NYU Grossman School of Medicine, targets toxic molecules released by all Staphylococcal bacteria, called leukocidins, rather than directly targeting the bacteria.

Key Points: 
  • The new vaccination strategy, developed by researchers at NYU Grossman School of Medicine, targets toxic molecules released by all Staphylococcal bacteria, called leukocidins, rather than directly targeting the bacteria.
  • Attempts to develop a Staphylococcal vaccine have so far failed, researchers say, in part because leukocidins kill immune system cells, or leukocytes, needed by the immune system to fight the infection and whose production is triggered by a vaccine.
  • "This strategy is based on maximum disarmament of the bacterium's ability to kill all types of immune system cells."
  • Torres says a "foolproof" vaccine against the bacteria, including MRSA, will likely involve targeting more than just its leukocidin toxins.

Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate

Tuesday, June 30, 2020 - 12:00pm

GAITHERSBURG, Md., June 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in the Companys Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate.

Key Points: 
  • GAITHERSBURG, Md., June 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in the Companys Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate.
  • The clinical trial is expected to enroll 42 healthy subjects who will receive intranasally administered NasoShield or placebo and be followed for 6 months.
  • The primary immunogenicity readouts are the serum titers of antibody to protective antigen and toxin-neutralizing antibody 28 and 56 days after dosing.
  • Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and intranasal vaccines.